The Effect of Imipramine on Early Information Processing
Information source: Bispebjerg Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunters
Intervention: imipramine (Drug)
Status: Active, not recruiting
Sponsored by: Bispebjerg Hospital
Official(s) and/or principal investigator(s):
Birte Glenthoj, MD, DMSc., Study Director, Affiliation: Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark
We wanted to compare the relation of two different psychophysiological paradigms (PrePulse
Inhibition of the startle response = PPI and P50 suppression) to each other. Additionally, we
wanted to test the effect of the combined serotonin- and noradrenaline re-uptake inhibitor,
imipramine, on these measures. The primary hypothesis was that PPI and P50 gating would not
correlate with each other at baseline. The secondary hypothesis was that increased
noradrenergic and serotonergic activity would disrupt PPI as well as P50 gating.
Official title: Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions
Study design: Diagnostic, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study
PrePulse Inhibition of the startle response
P50 ERP gating
Minimum age: 18 Years.
Maximum age: 35 Years.
- Male subjects
- Good Physical and Mental Health meeting criteria "never mentally ill", which will be
evaluated with a medical history checklist, ECG
- Non smokers
- Current use of any medication
- Any subject who has received any investigational medication within 30 days prior to
the start of this study
- History of neurologic illness
- History of psychiatric illness in first-degree relatives, evaluated with DSM-IV
- History of alcohol and drug abuse. Positive urine screening for amphetamine, cocaine,
cannabis, or esctacy.
Locations and Contacts
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup DK-2600, Denmark
Center for Neuropsychiatric Schizophrenia Research (CNSR)
Starting date: September 2004
Last updated: September 11, 2006